Application of Bioimpedance Vector Analysis in Neonates

Launched by ZHUJIANG HOSPITAL · Dec 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how body composition is measured in healthy newborns, specifically focusing on a method called bioimpedance vector analysis. The researchers want to find out if the way this measurement works for healthy neonates in China is similar to what has been observed in other countries. This study is observational, meaning that the researchers will simply be observing and recording data without providing any treatment.

To be eligible to participate, newborns must be healthy and born at full term, within 24 hours of birth. Parents or guardians need to give their consent for their baby to be part of the study. Unfortunately, infants with certain health issues or congenital problems cannot take part. If your newborn qualifies and you decide to participate, the study will involve measuring your baby’s body composition using a special device called the NUTRILAB impedance analyzer. This is a safe and non-invasive process, and it will help researchers gather valuable information about newborn health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy term neonates of both sexes within 24 hours.
• • 2. Neonates whose parents or guardians consent with the research.
• Exclusion Criteria:
• • 1. Infants with some disease and conditions that could interfere in the body composition (such as heart failure, blue light irradiation, sepsis, kidney injury, hepatic failure, transfusion) and newborns with congenital anomalies and/or genetic problems.
• • 2. Neonates whose parents or guardians refuse to participate in the research.